LY3454738

DRUG4 trials

Sponsors

Eli Lilly and Company

Conditions

Atopic DermatitisChronic Spontaneous UrticariaDermatitis, AtopicHealthy

Phase 1

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

CompletedNCT03750643

Eli Lilly and CompanyDermatitis, Atopic

Start: 2018-11-29End: 2021-09-07Updated: 2021-10-06

A Relative Bioavailability Study of LY3454738 in Healthy Participants

CompletedNCT06173895

Eli Lilly and CompanyHealthy

Start: 2024-01-12End: 2024-05-02Updated: 2024-05-30

Phase 2

A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria

TerminatedNCT04159701

Eli Lilly and CompanyChronic Spontaneous Urticaria

Start: 2019-11-15End: 2021-02-24Updated: 2022-03-11

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

TerminatedNCT05911841

Eli Lilly and CompanyAtopic Dermatitis

Start: 2023-06-21End: 2025-03-14Updated: 2025-12-02

Related Papers

Ucenprubart is an agonistic antibody to CD200R with the potential to treat inflammatory skin disease: preclinical development and a phase 1 clinical study

Nature Communications2025-05-012 citations